aTyr Pharma Announces Research Study with Stanford Medicine
Study to explore role of the Company’s anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common type of primary brain...
Clinical Trial
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024...
Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
SOL-R evaluates repeat AXPAXLI™ dosing for wet age-related macular degeneration (wet AMD) Global non-inferiority study comparing AXPAXLI, dosed every six...
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brainThese tools...
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung...
Cytokinetics Announces Call for Proposals for Corporate Giving Program
Program Augments Existing Patient Advocacy and Professional Society Donationsto Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is September...
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential...
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address...
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in...
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
Breakthrough Device Designations are granted by the U.S. FDA to expedite review of promising technologies that address high unmet needs...
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE...
Day One Announces Oversubscribed $175.0 Million Private Placement
BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
Foresight Diagnostics Expands Series B Financing to $73.75 Million to Advance the Foresight CLARITY™ MRD Platform
BOULDER, Colo., July 30, 2024 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”), a leading diagnostics company specializing in the development...
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally...
DEEP Launches a Platform to Build Digital Measures of Health
HELSINKI, Finland, July 30, 2024 /PRNewswire/ -- DEEP Measures announces its collaborative platform to build digital measures in clinical trials,...
German Medtech Protembis Gets €20 Million EIB Backing for Technology to Protect Brain During Heart Treatment
EIB offers Protembis venture debt for next-generation technology to reduce risk of brain injury in patients undergoing catheter-based heart treatment...
HRX 2024 IGNITES INNOVATION FOR CUTTING-EDGE BREAKTHROUGHS IN CARDIOVASCULAR MEDICINE AND DIGITAL HEALTH
Thought leaders, trailblazers, and advocates gather to explore the forefront of discoveries and advance partnerships between medicine and technology. ATLANTA,...
Datavant, Premier Inc, Privacy Analytics to Showcase Privacy Enhancing Technologies in Healthcare at Congressional Briefing
NEW YORK, July 29, 2024 /PRNewswire/ -- Datavant, the leading health data platform company, is proud to announce its participation in...
Boston University Announces Launch of SEQSTER’s 1-Click Records™ to Aid in Development of Early Alzheimer’s Screening Tool
The system will allow researchers to retrieve a person’s longitudinal health record in seconds. DxA-Funded Researcher and Goodes Prize Winner...